Trial Watch Edition 7 tracks 9 clinical trial signals across 4 therapy areas, based on 9 research sources from April 2026.
This edition highlights where clinical development activity is concentrating across cardiometabolic disease, oncology, infectious disease and rare disease.
The strongest signal comes from cardiometabolic programs, followed by oncology and rare disease activity, with infectious disease remaining a smaller but strategically relevant area.
The broader pattern is clear. Sponsors are continuing to build conviction around focused therapeutic areas where clinical demand, patient need and development urgency remain high.